ASX: CHM - Chimeric Therapeutics completes milestones in cell therapy trial for cancer patients

Wednesday, May 12, 2021 2:56 AM +00:00

CHIMERIC THERAPEUTICS LIMITED
Jennifer Chow

Chimeric Therapeutics, ASX:CHM, is a clinical stage cell therapy company focused on bringing cell therapy to patients with cancer. Today Boardroom.Media reporter Velvet-Belle Templeman is joined by Jennifer Chow, Chief Operating Officer of Chimeric Therapeutics to brief the market on their Chlorotoxin CAR T trial and clinical developments.


Leave a Comment

Your email address will not be published

WEBCAST Calendar

  • 10 May

    01:00

    First Quarter 2021 Conference Call May 7, 2021

    EOG RESOURCES
  • 10 May

    02:00

    Shot on iPhone 12 — Everyday Experiments: Full Bloom | Apple May 7, 2021

    APPLE INC
  • 10 May

    02:00

    Magmatic Resources - RIU Sydney Resources Round-up 6th May 2021

    MAGMATIC RESOURCES LIMITED
  • 10 May

    02:00

    Mike Young Vimy Resources (ASX:VMY) RIU 2021 Sydney Resources Roundup

    VIMY RESOURCES LIMITED
  • 10 May

    02:00

    Neometals staying focused on the global EV battery recycling opportunity 7th May 2021

    NEOMETALS LTD